It has been suggested that vitamin E alone or combined with other vitamins or minerals can prevent oxidative stress and slow oxidative injury-related diseases, such as cardiovascular disease and cancer. A comprehensive search of PubMed/MEDLINE, EMBASE and the Cochrane Library was performed. Relative risk was used as an effect measure to compare the intervention and control groups. A total of 33 trials were included in the metaanalysis. Neither vitamin E intake alone (RR51.01; 95% CI, 0.97 to 1.04; p50.77) nor vitamin E intake combined with other agents (RR50.97; 95% CI, 0.89 to 1.06; p50.55) was correlated with all-cause mortality. Subgroup analyses revealed that low-dose vitamin E supplementation combined with other agents is associated with a statistically significant reduction in all-cause mortality (RR50.92; 95% CI, 0.86 to 0.98; p50.01), and vitamin E intake combined with other agents is associated with a statistically significant reduction in mortality rates among individuals without probable or confirmed diseases (RR50.92; 95% CI, 0.86 to 0.99; p50.02). Neither vitamin E intake alone nor combined with other agents is associated with a reduction in all-cause mortality. But a low dose (,400 IU/d) of vitamin E combined with other agents is correlated with a reduction in all-cause mortality, and vitamin E intake combined with other agents is correlated with a reduction in the mortality rate among individuals without probable or confirmed diseases.
The aging of the population is one of most common phenomena in many countries, especially developed countries. With advancing age, people are more likely to develop CVD (cardiovascular disease) and cancer, the two leading causes of death. Free oxygen radicals increase levels of lipid peroxidation and damage DNA and other subcellular structures, contributing to the development of CVD and cancer (1-3). Therefore, extensive preclinical and observational studies have been conducted to evaluate the preventive effects of antioxidant vitamins and minerals against oxidative stress and oxidative injury-related chronic diseases (4-6).
Vitamin E is well-known as the most important lipid soluble antioxidant (7). In animal models, a-tocopherol, the active form of antioxidant vitamin E, has been associated with reductions in atherosclerotic lesions, smooth muscle cell proliferation and platelet adherence and aggregation (8-10). On the other hand, it has been widely demonstrated that vitamin E and certain other agents such as vitamin C (ascorbic acid), b-carotene and selenium cooperatively reduce oxidative stress (5, 6, 11, 12) . The antioxidant effects of vitamin E can be strengthened by vitamin C (5), b-carotene and selenium (11, 13) , and vitamin E can play a biochemical role that is analogous to the role of zinc in stabilizing membrane structure and reducing peroxidative damage (14). Vitamin E acts as the primary antioxidant and the resulting vitamin E radical then reacts with vitamin C to regenerate vitamin E (15).
However, meta-analyses evaluating the antioxidant effect of vitamin E have reported a disappointing effect on survival (16-20). Among these meta-studies, the most recent and systematic study was reported 9 y ago and demonstrated that low-dose vitamin E slightly but non-significantly decreased the mortality but high-dose vitamin E increased mortality (18). High dosage of vitamin E intake has been revealed to contribute to many clinical disorders (21), which is consistent with the increased mortality for high-dose vitamin E. Otherwise, another meta-study on vitamin E, which used the same inclusion criteria as Miller et al. (18) but adopted a different meta-analytic method, also got a disappointing result (22, 23) . Such an effect could obscure the effect of vitamin E in studies without considering the dosage, which is seen in several reports (16, 17, 19, 20) . The cooperative effect of vitamin E with other agents could also be concealed in studies pooling vitamin E alone and with other agents together, which is seen in several reports (16-18, 20, 22) . Moreover, 12 RCTs evaluating the effects of micronutrient supplementation including vitamin E on mortality and morbidity have been carried out between 2005 and 2013 and were not included in the previous meta-analysis (18) . Of the 12 RCTs, 4 trials found the anticipated trend. However, none of them was statistically significant. Therefore, it is urgent to perform a meta-analysis by differentiating between low dosage and high dosage and between vitamin E alone and combined with other agents (at least one of the vitamins or minerals that have been reported to cooperate with vitamin E) on all-cause mortality, thus to comprehensively evaluate the effects of vitamin E supplementation.
MATERIALS AND METHODS
Search strategy and assessment of studies. We searched PubMed/MEDLINE, EMBASE and the Cochrane Library (November 2013) for all RCTs that tested the effect of vitamin E for primary and secondary prevention. Various combinations of the following MeSH (medical subject heading) items were used: vitamin E, a-tocopherol, micronutrient, antioxidant, mortality, clinical trial and randomized controlled trial. The reference lists from reviews and previous meta-analyses were reviewed, and the studies that met the inclusion criteria were recorded.
Two reviewers (Shan Jiang and Zhenyu Pan) independently checked the title and abstract of every retrieved study, and if necessary, the full articles were retrieved for further assessment. In the case of duplicate reports, only the most recently published study was included. The other two reviewers (Hui Li and Fenglan Li) independently evaluated the methodological quality of these studies using the method recommended by the Cochrane Handbook for Systematic Review of Interventions. According to the Jadad scale, four components of methodological quality were assessed: randomization, allocation concealment, blinding and follow-up. Randomization was considered adequate if the allocation sequence was generated by a computer or a random number table and considered unclear if the trial was described as randomized, but the method used to generate the allocation sequence was not described. Allocation concealment was defined as adequate if the allocation of the patients involved a central independent unit, an on-site locked computer, identical numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes. Allocation concealment was considered unclear if the trial was described as randomized, but the method used to conceal the allocation was not described. Blinding was considered adequate if the trial was described as double-blinded and the method of blinding involved an identical placebo or active drugs; it was considered inadequate if the trial was not double-blinded. Follow-up was considered adequate if the numbers of dropouts and withdrawals from all of the intervention groups and their reasons were described or if the study specified that there were no dropouts or withdrawals. Follow-up was considered inadequate if the number of dropouts and withdrawals or their rea-sons were not described. Disagreements were resolved by consensus. Inclusion criteria. The following inclusion criteria were used to select studies for this analysis: (1) RCTs evaluating the efficacy of vitamin E; (2) assessment of vitamin E intake alone or combined with at least one of the following vitamins or minerals, which have been largely reported to interact with vitamin E: vitamin Randomization was considered to be adequate if the allocation sequence was generated by a computer or a random number table and considered unclear if the trial was described as randomized, but the method used to generate the allocation sequence was not described. Allocation concealment was defined as adequate if the allocation of the patients involved a central independent unit, an on-site locked computer, identical numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes. Allocation concealment was considered unclear if the trial was described as randomized, but the method used to conceal the allocation was not described.
Blinding was considered adequate if the trial was described as double-blinded and the method of blinding involved an identical placebo or active drugs; it was considered inadequate if the trial was not double-blinded. Follow-up was considered adequate if the numbers of dropouts and withdrawals from all of the intervention groups and their reasons were described or if the study specified that there were no dropouts or withdrawals. Follow-up was considered inadequate if the number of dropouts and withdrawals or their reasons were not described.
C, b-carotene, selenium and zinc;
(3) a study sample limited to men or non-pregnant women; (4) minimal vitamin E supplementation and a follow-up period of 1 y; and (5) a minimum of 10 deaths in the trial. The restriction to include studies of vitamin E intake combined with at least one of the vitamins or minerals mentioned above was made primarily to assess cooperative efficacy as much as possible. According to the previous meta-analysis about vitamin E supplementation (18), a minimum of 10 deaths was considered because we anticipate that some trials may not intentionally assess the efficacy of vitamin E on mortality, and the data was incomplete therefore Trials with a Jadad score of 4 or more were included. Data extraction. The data were extracted from each study using a standardized protocol to assess the number of participants enrolled in the study, the number of participants in the intervention and control arms, the population, the dosage of vitamin E, the combined agents and their dosages and the follow-up time frame. The dosage of vitamin E in each trial was converted into conventional international units. The year of publication and the mean age of the participants were also extracted. For the trials that evaluated two agents with a 232 or 23232 factorial design, we compared all of the participants receiving vitamin E to all of the participants not receiving it, and thus, these trials were regarded as vitamin E supplementation alone.
Statistical analyses. All of the statistical analyses were performed using Review Manager version 5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). The dichotomous data were expressed as RR (relative risk) values with 95% CIs. The heterogeneity among the studies was measured using the Cochrane Q statistic and assessed by calculating I 2 . The level was set at 0.05. If the Q statistic was significant, a random-effect model was assumed, otherwise a fixed-effect model was employed. Publication bias was analyzed by Begg's funnel plot and Egger's test. All above statistical analyses were performed using Revman 5.0. All RCTs were categorized to be either vitamin E intake combined with other agents or intake alone trials. In subgroup analyses, trials were subdivided according to daily dosage (,400 IU/d or 400 IU/d), age (,65 y old or 65 y old), health status and follow-up years.
RESULTS

Study selection
The detailed selection process is summarized in the flowchart (Fig. 1) . We identified 158 RCTs related to vitamin E. Twenty-six trials with infants and children and 6 trials with pregnant women were excluded based on their titles and/or abstracts. An additional 37 trials on acute and infectious diseases were also excluded because many of the diseases were fatal (e.g., SARS and AIDS) and could easily mask the efficacy of vitamin E. A total of 89 studies were retained for further assessment. Twelve trials with fewer than 10 deaths and 44 trials with insufficient data were also excluded. Ultimately, we included 33 RCTs of good methodological quality in the meta-analysis as shown in Table 1 (24-57). The assessment of the methodological quality of the included trials is shown in Table 2 . Of all the trials, 19 focused on vitamin E intake alone, and 14 focused on vitamin E combined with other agents. The dosage of administered vitamin E varied between 11 and 5,000 IU/d, with a median dosage of 400 IU/d, and the duration of follow-up varied between 1 y and 10.1 y, with a mean follow-up period of 4.225 y.
Effect of vitamin E intake combined with other agents on allcause mortality
A total of 14 trials was included in this group. Overall, vitamin E intake combined with other agents did not affect all-cause mortality. The pooled RR for the intervention groups compared with the control groups was 0.97 (95% CI, 0.89 to 1.06; p50.55) (Fig. 2) . The subgroup analyses demonstrated a significant decrease in all-cause mortality with low-dose vitamin E supplementation and in the subgroup of individuals without probable or confirmed diseases, but there was no decrease in the high-dose subgroup or the subgroup of individuals with probable or confirmed diseases. The pooled RR of the low-dose group was 0.92 (95% CI, 0.86 to 0.98; p50.01), and the pooled RR for the high-dose group was 1.28 (95% CI, 0.81 to 2.03; p50.29) ( Table 3) . The pooled RRs for the individuals without probable or confirmed diseases and the individuals with probable or confirmed diseases were 0.92 (95% CI, 0.86 to 0.99; p50.02) and 1.02 (95% CI, 0.86 to 1.21; p50.81), respectively (Table 3) . Other subgroup variables, including age and follow-up year, did not produce statistically significant results. The funnel plot showed an asymmet-ric pattern because of several specific trials; however, Egger's regression test suggested that there was no publication bias in the meta-analysis (p50.630) (Fig. 3) .
Effect of vitamin E intake alone on all-cause mortality
A total of 15 trials were included in this group. Overall, vitamin E intake alone has no effect on all-cause mortality. The pooled RR for the intervention groups compared with the control groups was 1.01 (95% CI, 0.97 to 1.04; p50.77) (Fig. 4) . The subgroup analyses of low-dose and high-dose vitamin E intake alone Fig. 3 
. Funnel plot on publication bias for trials on vitamin E intake combined with other agents. p-value is derived from
Egger's regression test. (Table 4) . Other subgroup variables, including age, health status and follow-up year, did not produce any statistically significant results. The funnel plot and Egger's regression test suggested that there was no publication bias in the meta-analysis (p50.660) (Fig. 5) .
DISCUSSION
A large amount of recent epidemiological data provide some evidence that concomitant use of vitamin E with other agents has beneficial impacts on mortality from CVD or cancer or all-cause mortality. Some of them showed a statistically non-significant decrease in cause-specific and all-cause mortality rates (25, 26, 30, 32) . One trial published in the early nineties revealed a statistically significant decrease in all-cause mortality (27). However, about half of the trials got unanticipated results or trends on mortality. Moreover, several metaanalyses on vitamin E did not show its beneficial role, and even suggested that vitamin E is harmful to human health. The current meta-analysis demonstrated that only low-dose vitamin E combined with other agents decreases all-cause mortality. The subgroup analysis by health status further indicated that the efficacy of lowdose vitamin E intake combined with other vitamins or minerals on mortality was confined to individuals without probable or confirmed diseases. Our meta-analysis showed that low-dose vitamin E alone, high-dose vitamin E alone or high-dose vitamin E in combination with other agents does not decrease or increase all-cause mortality. A recent meta-analysis conducted by Miller et al. (18) reported that all-cause mortality was slightly, but non-significantly, decreased by vitamin E at doses of less than 150 IU/d. In our analysis, vitamin E doses in all low-dose vitamin E intake combined with other agents trials (,400 IU/d) were less than 150 IU/d (Table 1) . Thus, we speculate that the slight decrease of mortality observed by Miller et al. (18) could be attributed to the efficacy from low-dose intake combined with other agents. However, a meta-study, which utilized the same criteria as Miller et al. (18) but adopted different meta-analytic method, reported that vitamin E intake was unlikely to affect mortality regardless of the dose of its intake (22). Many previous experimental trials have demonstrated that high doses of vitamin E encourage prooxidative activity (58, 59) , and can cause many clinical disorders, such as thrombophlebitis, pulmonary embolism, nausea, diarrhea and intestinal cramps (21, 60, 61) . The meta-analysis conducted by Miller et al. showed that high-dosage supplementation of vitamin E can increase all-cause mortality (18). Many researchers have warned against the clinical administration of high doses of vitamin E (62) . Of 19 trials included in our analysis of the effect of high-dose vitamin E, 12 trials revealed statistically non-significant increases in mortality with high-dose vitamin E alone. However, meta-analysis of these 19 trials demonstrated that high-dose vitamin E did not increase the mortality. This result suggests that the harmful effects of highdose vitamin E may not noticeably affect mortality.
Some researchers have suggested that a decrease in immune function predictably accompanies the aging process (63) , and many preclinical and observational studies have demonstrated that micronutrient supplementation can enhance immune function, which is strongly related to cancer risk and the process of cancer development (64, 65) . Therefore, elderly people could improve their immune function by supplementing multiple micronutrients, and mortality and morbidity could be reduced. Moreover, it is well known that fruits and vegetables are rich in multiple micronutrients, and many epidemiological studies have revealed the beneficial effects of fruit and vegetable intake on the risk of CVD, cancer, and mortality attributable to these diseases (66, 67) . The intake of multiple vitamins and minerals is equivalent to fruit and vegetable consumption to some extent. Thus, these effects could contribute to the beneficial effects of low-dose vitamin E combined with other agents.
There are some weaknesses that may limit the generalization of this meta-analysis. Our search strategy did not identify any trials with Africans. Only trials published in English were included, so there might also be a language bias.
In conclusion, our study demonstrates that the consumption of low doses of vitamin E combined with other micronutrients can decrease all-cause mortality and should be recommended to the general population, at least according to our speculation of the results of the subgroup analyses. In the future, recently completed trials and other ongoing trials will provide more precise information on the relationship between multimicronutrient intake and all-cause mortality. 
CONCLUSION
Neither vitamin E intake alone nor combined with other agents is associated with a reduction in all-cause mortality. But a low dose (,400 IU/d) of vitamin E combined with other agents is correlated with a reduction in all-cause mortality, and vitamin E intake combined with other agents is correlated with a reduction in the mortality rate among individuals without probable or confirmed diseases.
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